Ademetionine in Obstructive Hypertrophic Cardiomyopathy

Inclusion Criteria: * Meet the diagnostic criteria for HCM. * Age ≥ 18 years at screening. * LVEF ≥ 50% at screening. * Echocardiography demonstrates a resting or provoked LVOTG ≥ 30 mmHg at screening. * NYHA Functional Class II-III at screening. * Able to perform CPET. * Patients receiving treatment with β-blockers or non-dihydropyridine calcium channel blockers should have been on a stable dose for at least 6 weeks prior to randomization and are expected to maintain the same medication during the trial. Who have previously received cardiac myosin inhibitors (e.g., Mavacamten) must discontinue the treatment for at least 8 weeks prior to randomization. * Willing and able to sign the informed consent form and comply with all scheduled study visits. Exclusion Criteria: * History of severe hypersensitivity to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets. * History of psychiatric disorders, or current use of antidepressants such as clomipramine. * Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period. * Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period. * Currently pregnant or planning pregnancy. * Currently participation in another drug or device clinical trial. * History of any other disease with a life expectancy of less than 1 year.